Dr. Howard Colman, MD

Dr. Colman practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Colman's NPI, 1437258498, was assigned on September 22, 2006. Dr. Colman graduated from Washington University School of Medicine in 1997. Dr. Colman holds Utah license 7665006-1205.

Dr. Colman's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Colman's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Colman is also affiliated with University of Utah Hospital. The medical group on file is Intermountain Health. Dmand AI also links Dr. Colman to 3 more group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Colman practices, 5 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Colman's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Colman is licensed in Utah.

CMS data shows 223 Medicare services from Dr. Colman across 4 procedure codes in 2024, for 59 Medicare patients. Medicare paid $15,145 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 59 Medicare patients who saw Dr. Colman in 2024. The largest group is 65 to 74, with 30 patients. 56% of them have high blood pressure, and 42% have depression. Their average risk score is 1.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Colman's median patient age at 57, with 50% women.

In 2024, Dr. Colman wrote 72 Medicare Part D claims for 22 patients. 67% of them were for generic drugs. CMS names the drug for 24 of them, across 2 drugs with 11 or more claims each, at $366,687 in total drug cost. In 2023, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Colman for performance year 2024, reported as part of a group. Dr. Colman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Colman as offering telehealth.

Dmand AI links 89 papers to Dr. Colman, published from 2010 to 2025. 2024 was the busiest year, with 8. The most frequent topics are Brain Neoplasms, Glioma and Glioblastoma. Dr. Colman has published most often in J Neurooncol. Dr. Colman's most frequent co-authors are Frederick F. Lang, MD, Mark Raymond Gilbert, MD and Vinay K. Puduvalli, MD.

Dmand AI links Dr. Colman to 10 clinical trials, 4 of them phase 1/2 studies. 5 are still active or recruiting. Conditions studied include Glioblastoma, Gliosarcoma and Astrocytoma. Alliance for Clinical Trials in Oncology sponsors the most, 3.

CMS Open Payments shows 84 general payments to Dr. Colman from 15 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. Genentech, Inc. paid the most, $24,983. It also lists 11 research payments totaling $11,829 from 2016 to 2025.

Dr. Colman graduated from Washington University School of Medicine in 1997.